Effectiveness and safety evaluation of terlipressin in the treatment of intestinal paralysis in end-stage liver disease

Table 1 General characteristics of patients with intestinal paralysis

	Terlipressin treatment group (n = 33)	Conventional treatment group (n = 98)	P
Age	55.0 (49.0, 62.5)	55.0 (47.0, 63.0)	0.941
Sex			0.113
Male, n (%)	30 (90.9%)	77 (78.6%)
Female, n (%)	3 (9.1%)	21 (21.4%)
Etiology			0.413
HBV	22 (66.7%)	64 (65.3%)
HCV	0(0%)	5 (5.1%)
Alcoholic	9 (27.3%)	16 (16.3%)
Immune-related	1 (3.0%)	9 (9.2%)
Others	1 (3.0%)	4 (4.1%)
Cirrhosis	30 (90.9%)	91 (92.9%)	1.000
Hepatic cancer	8 (24.2%)	33 (33.7%)	0.312
Abdominal infections	33 (100%)	88 (89.8%)	0.126
Ascites			0.154
null	1 (3.0%)	14 (14.3%)
mild	7 (21.2%)	30 (30.6%)
moderate	9 (27.3%)	20 (20.4%)
large	16 (48.5%)	34 (34.7%)
Child-Pugh score			0.357
A	2 (6.1%)	11 (11.2%)
B	12 (36.4%)	44 (44.9%)
C	19 (57.6%)	43 (43.9%)

HBV, Hepatitis B Virus; HCV, hepatitis C virus
131 patients with end-stage liver disease (ESLD) and intestinal paralysis were enrolled in this study. 98 were assigned to the conventional treatment group, with 77 males and 21 females. The median age of these patients was 55.0 (47.0, 63.0) years. Among the etiologies of ESLD, patients with HBV totaled 64, HCV 5, alcoholic cirrhosis 16, immune-related cirrhosis 9, and other reasons 4. The remaining 33 patients were included in the terlipressin treatment group, including 30 males and 3 females, with a median age of 55.0 (49.0, 62.5) years. Among the etiologies of ESLD, 22 had HBV, 9 alcoholic cirrhosis, 1 immune-related cirrhosis, and 1 other causes. There were no significant differences in age, sex, etiology, cirrhosis, hepatic cancer, abdominal infection, ascites and Child-Pugh classification between two groups (p > 0.05)

ISSN: 1471-230X